Trial · NCT02249247
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in exercise endurance | Pre-dose, up to 12 weeks after start of treatment | evaluated by constant work load test |
| Secondary | Changes in breathlessness during constant work load test | Week 4 and week 12 weeks after start of treatment | measured by Modified Borg scale: Dyspnea score, leg discomfort |
| Secondary | Changes in forced expiratory volume in one second (FEV1) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in forced vital capacity (FVC) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in forced expiratory flow at 25%-75% of FVC (FEF25-75%) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in inspiratory capacity (IC) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in slow vital capacity (SVC) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Change in thoracic gas volume | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
| Secondary | Changes in total lung capacity | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
| Secondary | Changes in residual volume | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
| Secondary | Changes in specific airway conductance | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
| Secondary | Changes in Mahler dyspnoea questionnaire | Pre-dose, up to 12 weeks after start of treatment | Baseline dyspnoea index / transitional dyspnoea index (BDI/TDI) |
| Secondary | Changes in chronic respiratory disease questionnaire (CRDQ) | Pre-dose, up to 12 weeks after start of treatment | |
| Secondary | Changes in carbon monoxide diffusing capacity (DLco) | Pre-dose, up to 12 weeks after start of treatment | |
| Secondary | Changes in diffusing capacity of carbon monoxide corrected for alveolar volume (DLco/VA) | Pre-dose, up to 12 weeks after start of treatment | |
| Secondary | Changes in peak expiratory flow rate (PEFR) daily patient record | Pre-dose, up to 14 weeks after start of treatment | assessed a.m. and p.m. in daily patient record |
| Secondary | Changes in 24-hours spontaneous sputum wet weight | Pre-dose, up 12 weeks after start of treatment | |
| Secondary | Changes in oxygen saturation during constant work load test | Pre-dose, up to 12 weeks after start of treatment | assessed by pulse oximetry |
| Secondary | Changes in global evaluation assessed by investigator on a 4-point scale | Pre-dose, up to 14 weeks after start of treatment | |
| Secondary | Clinically relevant changes in vital signs (pulse rate, blood pressure) | Pre-dose, up to 14 weeks after start of treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02249247/registered